Development and validation of a polygenic hazard score to predict prognosis and adjuvant chemotherapy benefit in early-stage non-small cell lung cancer [0.03%]
早期非小细胞肺癌预后和辅助化疗效益的多基因危险评分的开发和验证
Dan-Hua Li,Yong-Qiao He,Tong-Min Wang et al.
Dan-Hua Li et al.
Background: It remains controversial who would benefit from adjuvant chemotherapy (ACT) in patients with early-stage non-small cell lung cancer (NSCLC). We aim to construct a polygenic hazard score (PHS) to predict progno...
Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer-a retrospective study [0.03%]
小细胞肺癌偶然切除的有限病灶患者的辅助治疗-一项回顾性研究
Kai-Qi Jin,Xiao-Gang Liu,Yan-Hua Guo et al.
Kai-Qi Jin et al.
Background: With the exception of very early-stage small cell lung cancer (SCLC), surgery is not typically recommended for this disease; however, incidental resection still occurs. After incidental resection, adjuvant sal...
Value of 18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in the differential diagnosis of sarcoidosis and lung cancer with lymph node metastasis: a retrospective study [0.03%]
氟脱氧葡萄糖正电子发射断层显像/ computed tomography 检查在淋巴结肿大型肺结核和肺癌伴淋巴结转移鉴别诊断中的价值：一项回顾性研究
Xianqiu Chen,Xin Xu,Serafeim Chrysikos et al.
Xianqiu Chen et al.
Background: Fluorine 18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) has been proven to be valuable in guiding the diagnosis and management of sarcoidosis. However, its differential...
International expert consensus on immunotherapy for early-stage non-small cell lung cancer [0.03%]
早期非小细胞肺癌免疫治疗国际专家共识
Wenhua Liang,Kaican Cai,Qingdong Cao et al.
Wenhua Liang et al.
PTS is activated by ATF4 and promotes lung adenocarcinoma development via the Wnt pathway [0.03%]
ATF4激活的PTS通过Wnt信号通路促进肺腺癌发生发展
Wei Ma,Chao Wang,Ruzhen Li et al.
Wei Ma et al.
Background: The effects and mechanism of 6-pyruvoyl-tetrahydropterin synthase (PTS) on lung adenocarcinoma (LUAD) were studied in LUAD cells and mice with subcutaneously transplanted tumors. ...
Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis of cohort studies [0.03%]
免疫检查点抑制剂治疗对伴发间质性肺病的晚期非小细胞肺癌患者的疗效及危害：队列研究系统评价和.meta.分析
Kinnosuke Matsumoto,Takayuki Shiroyama,Tomoki Kuge et al.
Kinnosuke Matsumoto et al.
Background: There is no clear consensus regarding the safety and efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC) and pre-existing interstitial lung disease (ILD...
Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer [0.03%]
KRAS突变非小细胞肺癌患者T细胞受体库的全面分析
Yadong Wang,Ling Peng,Ming Zhao et al.
Yadong Wang et al.
Background: Kirsten rat sarcoma viral oncogene homolog (KRAS) is one of the most frequently mutated oncogenes in non-small cell lung cancer (NSCLC). The administration of immunotherapy has demonstrated significant efficac...
Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer [0.03%]
探索免疫检查点抑制剂联合抗血管生成疗法用于EGFR或ALK阳性晚期非小细胞肺癌患者的治疗
Andrea De Giglio,Alessandro Di Federico,Giulio Metro
Andrea De Giglio
Circulating tumor DNA accurately predicts disease progression and genotype alterations in postoperative adjuvant EGFR-TKI resistance: a case report [0.03%]
循环肿瘤DNA准确预测术后辅助EGFR-TKI耐药患者的病情进展和基因型改变：病例报告
Zhen Zeng,Chengwu Liu,Senyi Deng et al.
Zhen Zeng et al.
Background: Circulating tumor DNA (ctDNA) is receiving more and more attention for its role in tumor screening and disease surveillance in cancer patients. However, it is unclear whether ctDNA can be used to predict recur...
Lung function impairment in the German Lung Cancer Screening Intervention Study (LUSI): prevalence, symptoms, and associations with lung cancer risk, tumor histology and all-cause mortality [0.03%]
德国肺癌筛查干预研究(LUSI)中的肺功能损伤：流行率、症状与肺癌风险、肿瘤组织学和全因死亡率之间的关联
Rudolf Kaaks,Evangelia Christodoulou,Erna Motsch et al.
Rudolf Kaaks et al.
Background: Lung cancer screening may provide a favorable opportunity for a spirometry examination, to diagnose participants with undiagnosed lung function impairments, or to improve targeting of computed tomography (CT) ...